Medical experts and advocates are warning that treating obesity as a personal lifestyle failure rather than a chronic medical condition is creating dangerous barriers to effective care. This misconception often leads to insurance denials and limited access to life-changing medications across North America and globally.

Why is access to obesity medication restricted?

Even as new GLP-1 therapies transform treatment, many patients struggle to obtain them. In the United States, research presented at ObesityWeek 2026 revealed that over 35% of first-time requests for prior authorization for these drugs were rejected. Common reasons for these denials include eligibility mismatches and specific plan exclusions.

In Canada, the landscape varies by province. While Alberta recognized obesity as a disease in early 2025, Quebec has only recently begun a pilot project to determine if provincial healthcare should cover certain obesity medications. These regional differences mean that a patient's ability to access treatment often depends on their location.

The impact of medical stigma

Beyond insurance, social and professional stigma remains a major obstacle. Advocates note that the prevailing belief that obesity is merely a lack of willpower or discipline prevents many from seeking help. This "diet culture" can lead to patients feeling they must prove they are "worthy" of medical intervention.

Experts emphasize that obesity is a complex, multifactorial condition influenced by:

  • Genetics and biology
  • Environmental factors
  • Metabolic processes

Moving toward comprehensive care

Clinicians are being encouraged to move away from the search for a "magic pill" and toward personalized, long-term strategies. Because obesity is a chronic condition, effective management often requires a combination of tools. This may include intensive lifestyle interventions, behavioral programs, other established medications, or bariatric surgery.

Addressing obesity early is considered a vital form of prevention. Proactive treatment can potentially mitigate hundreds of downstream health impacts, reducing the long-term burden on healthcare systems and improving individual life expectancy.